In this podcast episode, we discuss the journey of novel modalities in rare disease treatment to patients, particularly advancements in oncology and the increasing role of patients' families in ...

Gain leadership and innovation insights from CEO of the Year finalist at 2025 CPHI Pharma Awards, Mahler Hanns-Christian, who ...

The CNPV pilot program significantly reduces review times, but may challenge safety standards and resource allocation.

Artificial intelligence (AI) and machine learning (ML) tools offer an ultra-material-sparing approach to accelerate ...

Unlock the potential of high-purity methylcellulose in biotech. Join our upcoming webinar to explore how METHONOVA™ enhances ...

In particular, Konagurthu says, AI/ML can help sift through a field of drug candidates in which the percentage that are ...

To meet rising demand, developers of precision radiopharmaceutical therapies must overcome challenges in global isotope ...

When we do things like quantum calculations, we look at the confirmer space. So what that does is give us insight into how a ...

The emerging prevalence of digitalization is a key topic for manufacturers handling excipients. Digital transformation and ...

Data integrity, impurity characterization, and stability requirements are key focus areas in drug substance testing, with advanced analytical technologies enhancing accuracy. Newer modalities, ...

Mechanistic models and hypothesis-driven strategies generate optimized efficient solutions for drug development, says ...

SMA is a rare, genetic neuromuscular condition that affects people across age groups. With treatment landscapes evolving ...